No Data
No Data
Mayinglong Pharmaceutical Group (600993.SH): The pharmaceutical registration certificate has been obtained for the moxifloxacin hydrochloride eye drops.
Mayinglong Pharmaceutical Group (600993.SH) announced that its wholly-owned subsidiary, Jiangxi Mayinglong Meikang Pharmaceutical Co., Ltd., has received the Drug Registration Certificate issued by the National Medical Products Administration for Moxifloxacin Hydrochloride Eye Drops. Moxifloxacin Hydrochloride Eye Drops is a fourth-generation fluoroquinolone antibacterial drug with broad-spectrum antibacterial activity.
Unpleasant Surprises Could Be In Store For Mayinglong Pharmaceutical Group Co., Ltd.'s (SHSE:600993) Shares
Mayinglong Pharmaceutical Group (600993.SH) plans to distribute a dividend of 0.4 yuan per share for the 2023 fiscal year, with ex-dividend on July 26th.
Mayinglong Pharmaceutical Group (600993.SH) announced that it plans to distribute a cash dividend of 0.4 yuan per share for the year 2023.
Mayinglong Pharmaceutical Group (600993.SH): Di Kua Linsuo Sodium Eye Drops Obtains Pharmaceutical Registration Certificate
Mayinglong Pharmaceutical Group (600993.SH) announced that its wholly-owned subsidiary, Jiangxi Mayinglong Meikang Pharmaceutical Co., Ltd., has received the Drug Registration Certificate approved and issued by the National Medical Products Administration for Diquafosol Sodium Eye Drops. Diquafosol Sodium Eye Drops are suitable for dry eye patients diagnosed with corneal epithelial injury caused by abnormal tear fluid, which was first approved for marketing in Japan in 2010 and for importation of original research in China in 2017.
We Think Mayinglong Pharmaceutical Group (SHSE:600993) Can Manage Its Debt With Ease
Mayinglong Pharmaceutical Group Co., Ltd. (SHSE:600993) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected
No Data